Drug Trial Radar · NCT01678898
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
Last checked: Nov 20, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Oct 2012
Primary completion
Mar 6, 2016
Study completion Mar 6, 2016
Sponsor
- Lead sponsor
- ProtalixIndustry
- Sponsor type
- Industry
- Collaborators
- Chiesi Farmaceutici S.p.A.
- First posted
- Sep 5, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is the first human treatment with PRX-102, an enzyme being developed as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (alpha galactosidase deficiency). The safety, tolerability, and exploratory efficacy will be evaluated in this study of increasing doses. Patients will be treated with infusions every two weeks for 12 months.
Conditions
- Fabry Disease
Interventions
PRX-102Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: 12 months
Locations
14 sites in 6 countries. Site status is shown where the registry gives one.
UC Davis Medical Center, MIND Institute Department of Pediatrics, Section of Genetics
Sacramento, California
Department of Human Genetics, Emory University School of Medicine
Atlanta, Georgia
University of Iowa Health Clinics
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
Johns Hopkins University School of Medicine
Baltimore, Maryland
Duke University Medical Center
Durham, North Carolina
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania
Research Baylor Institute of Metabolic Disease
Dallas, Texas
O & O Alpan LLC
Fairfax, Virginia
Royal Melbourne Hospital
Victoria Park, Australia
Hematology and Clinical Research Private Institute
Asunción, Paraguay
Clinical Center of Serbia
Belgrade, Serbia
Hospital de Dia Quiron Zaragoza
Zaragoza, Spain
The Royal Free Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.